Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

Authors

  • Boyu Li Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Ying Wang Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Zhikang Ye Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Hui Yang Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Xiangli Cui Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Zhenjun Wang Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Lihong Liu Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

DOI:

https://doi.org/10.18433/jpps29831

Abstract

PURPOSE: Non-alcoholic fatty liver disease (NAFLD) affects about 75% of patients with type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to determine the effect of canagliflozin on fatty liver indexes in T2DM patients. METHODS: A literature search of PubMed, Embase and Cochrane was conducted up to March 30, 2017. The liver function test and lipid profile were extracted from randomized controlled trials (RCTs) to evaluate the effect of canagliflozin on fatty liver. Weighted mean differences (WMDs) or relative risks and 95% confidence intervals (CIs) were computed by using either fixed or random-effects models. Sensitivity analysis and publication bias were evaluated. RESULTS: Our results showed that canagliflozin decreased serum concentrations of  alanine amino transferase (WMD: -11.68 [95% CI: -18.95, -10.95]; P<0.001), aspartate amino transferase (WMD: -7.50 [95% CI: -10.61, -4.38]; P<0.001), gamma-glutamyl transferase (WMD: -15.17 [95% CI: -17.73, -12.61]; P<0.001), triglycerides (WMD: -0.10 [95% CI: -0.15, -0.05]; P<0.001) but increased low-density lipoprotein cholesterol (WMD: 0.1 [95% CI: 0.06, 0.13]; P<0.001), high-density lipoprotein cholesterol (WMD: 0.06 [95% CI: 0.05, 0.07]; P<0.001) at week 26 or 52. CONCLUSIONS: Our results indicated that canagliflozin may have a protective effect on fatty liver in T2DM patients. The limitation was that the liver biopsy was hard to obtain in published studies. More RCTs specified on NAFLD are needed to get further information.

 

This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Downloads

Download data is not yet available.

Downloads

Published

2018-06-24

How to Cite

Li, B., Wang, Y., Ye, Z., Yang, H., Cui, X., Wang, Z., & Liu, L. (2018). Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. Journal of Pharmacy & Pharmaceutical Sciences, 21(1), 222–235. https://doi.org/10.18433/jpps29831

Issue

Vol. 21 (2018): Pages 143 - 304

Section

Systematic Review and Meta-Analysis

License

This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.

CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.